NZ629136A - Phytocannabinoids in the treatment of cancer - Google Patents

Phytocannabinoids in the treatment of cancer

Info

Publication number
NZ629136A
NZ629136A NZ629136A NZ62913611A NZ629136A NZ 629136 A NZ629136 A NZ 629136A NZ 629136 A NZ629136 A NZ 629136A NZ 62913611 A NZ62913611 A NZ 62913611A NZ 629136 A NZ629136 A NZ 629136A
Authority
NZ
New Zealand
Prior art keywords
containing component
phytocannabinoid
principal
fraction
phytocannabinoids
Prior art date
Application number
NZ629136A
Other languages
English (en)
Inventor
Alan Sutton
Sharon Anavi-Goffer
Aniello Schiano Moriello
Marzo Vincenzo Di
Alessia Ligresti
Ruth Alexandra Ross
Manuel Guzman
Petrocellis Luciano De
Geoffrey Guy
Angelo Antonio Izzo
Daniela Parolaro
Guillermo Velasco
Tetsuro Kikuchi
Paola Massi
Stephen Wright
Gabriella Aviello
Francesca Borelli
Sofia Torres
Meijer Etienne De
Mar Lorente
Colin Stott
David Potter
Lesley Ann Ford
Original Assignee
Gw Pharma Ltd
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42261478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ629136(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gw Pharma Ltd, Otsuka Pharma Co Ltd filed Critical Gw Pharma Ltd
Publication of NZ629136A publication Critical patent/NZ629136A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ629136A 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer NZ629136A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1004137.4A GB2478595B (en) 2010-03-12 2010-03-12 Phytocannabinoids in the treatment of glioma
NZ602953A NZ602953A (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ629136A true NZ629136A (en) 2016-03-31

Family

ID=42261478

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ629136A NZ629136A (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer
NZ602953A NZ602953A (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ602953A NZ602953A (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer

Country Status (28)

Country Link
US (3) US8790719B2 (enExample)
EP (1) EP2544682B1 (enExample)
JP (1) JP5785569B2 (enExample)
KR (1) KR20130067248A (enExample)
CN (1) CN102869356A (enExample)
AR (1) AR080454A1 (enExample)
AU (3) AU2011225837A1 (enExample)
BR (1) BR112012023017A8 (enExample)
CA (1) CA2792722A1 (enExample)
CO (1) CO6630103A2 (enExample)
CY (1) CY1117451T1 (enExample)
DK (1) DK2544682T3 (enExample)
EA (1) EA201290901A1 (enExample)
ES (1) ES2569669T3 (enExample)
GB (1) GB2478595B (enExample)
HR (1) HRP20160427T1 (enExample)
HU (1) HUE029817T2 (enExample)
IL (1) IL221871A (enExample)
MX (1) MX2012010512A (enExample)
NZ (2) NZ629136A (enExample)
PH (1) PH12012501782A1 (enExample)
PL (1) PL2544682T3 (enExample)
SG (1) SG184016A1 (enExample)
SI (1) SI2544682T1 (enExample)
TW (1) TWI461205B (enExample)
UA (1) UA109271C2 (enExample)
WO (1) WO2011110866A1 (enExample)
ZA (1) ZA201207574B (enExample)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
AU2005305675B2 (en) 2004-11-16 2012-12-13 Jazz Pharmaceuticals Operations Uk Limited New use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2460672B (en) * 2008-06-04 2012-01-04 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2494461A (en) * 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
US9776014B2 (en) 2012-05-03 2017-10-03 Magdent Ltd. Bone enhancement device and method
CA2895805A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
JP6581509B2 (ja) 2013-02-28 2019-09-25 ティーウィノット テクノロジーズ リミテッド 化合物を合成する化学工学プロセス及び装置
EP2968259B1 (en) 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
WO2014145490A2 (en) 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
US10441617B2 (en) 2013-03-15 2019-10-15 Biotech Institute, Llc Breeding, production, processing and use of medical cannabis
GB2513167B (en) 2013-04-18 2016-03-02 Otsuka Pharma Co Ltd Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
GB2516814B (en) * 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
US20160279073A1 (en) * 2013-10-31 2016-09-29 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
CA2992923C (en) 2014-07-21 2021-06-29 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal and sublingual administration of cannabinoids
AU2015308136B2 (en) 2014-08-25 2020-07-09 Teewinot Technologies Limited Apparatus and methods for the simultaneous production of cannabinoid compounds
WO2016044370A1 (en) 2014-09-16 2016-03-24 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
US9844518B2 (en) 2014-09-30 2017-12-19 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CA3135893C (en) * 2014-10-21 2023-11-14 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
CN104277917B (zh) * 2014-10-24 2018-02-09 汉康(云南)生物科技有限公司 一种富含大麻二酚的工业大麻精油提取方法及其提取设备
US10502750B2 (en) 2014-12-23 2019-12-10 Biotech Institute, Llc Reliable and robust method for the analysis of cannabinoids and terpenes in cannabis
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
CA3012599A1 (en) 2015-01-26 2016-08-04 Matthew W. Giese Systems, apparatuses, and methods for classification
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
US20160250270A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
EP3277260B1 (en) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Erodium crassifolium l'her plant extracts and uses thereof
JP2018515608A (ja) * 2015-05-07 2018-06-14 シャルダン, マーク アンドリューSCIALDONE, Mark Andrew カンナビスオイルの水素化
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
EP3319446A4 (en) * 2015-07-06 2019-07-03 Cg- Bio Genomics, Inc. Healthful supplements
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
EP3380096A4 (en) * 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
MX421795B (es) * 2016-03-18 2025-03-14 Christopher Brian Reid Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2017218629A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
AU2017307644B2 (en) * 2016-08-03 2019-06-20 Zelira Therapeutics Operations Pty Ltd Cannabis composition
WO2018023166A1 (en) * 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
KR20190035791A (ko) * 2016-08-03 2019-04-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
CA3034004C (en) 2016-08-29 2021-08-03 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
AU2018227544A1 (en) * 2017-03-01 2019-08-29 Canopy Growth Corporation Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
CN110621312A (zh) * 2017-03-05 2019-12-27 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 用于治疗癌症的组合物和方法
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
CN110913839A (zh) * 2017-05-22 2020-03-24 Gbs全球生物制药公司 靶向trpv1的含月桂烯和大麻素的组合物
AU2018286647B2 (en) 2017-06-19 2024-03-28 Zelira Therapeutics Operations Pty Ltd Sleep disorder compositions and treatments thereof
DK3509638T3 (da) 2017-06-20 2022-04-11 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Præparater med cannabidiolsyreestere og anvendelser deraf
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
IL304777B1 (en) * 2017-06-28 2026-02-01 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid products for women's health
CA3079537A1 (en) * 2017-09-02 2019-03-07 Scientific Holdings, Llc Tetrahydrocannabinol modulators
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
CN108204786A (zh) * 2018-01-15 2018-06-26 武汉盛硕电子有限公司 一种基于手机模块的北斗测量系统
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
CA3096287A1 (en) * 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
BR112020016074A2 (pt) 2018-02-08 2020-12-08 Neonc Technologies, Inc Métodos de permeabilização da barreira hematoencefálica
KR20190098649A (ko) 2018-02-14 2019-08-22 (주)카이언바이오텍 칸나비디올 추출물을 함유하는 대장암 예방 또는 치료용 약학 조성물
KR102041875B1 (ko) 2018-02-14 2019-11-08 (주)카이언바이오텍 대마로부터 추출된 칸나비디올 추출물 및 트레일을 함유하는 대장암 예방 또는 치료용 약학 조성물
JP7293561B2 (ja) * 2018-02-20 2023-06-20 マイエムディー ファーマスーティカルズ、インコーポレイテッド 薬物中毒および他の障害の治療のための遺伝子組み換え大麻植物および組み換えカンナビノイド化合物
MX2020010284A (es) 2018-03-30 2021-02-18 India Globalization Capital Inc Método y composición para el tratamiento de los trastornos del snc.
EP3773722A1 (en) 2018-04-04 2021-02-17 Jay Pharma Inc. Combination of a cannabinoid and a chemotheraopeutic agent for the treatment of breast cancer
BR112020020850A2 (pt) 2018-04-09 2021-01-19 Ellevet Sciences Extrato de cânhamo para tratamento da dor em animais
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
WO2020012315A1 (en) * 2018-07-08 2020-01-16 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid composition for treatment of male subjects
EP3666765A1 (en) * 2018-12-11 2020-06-17 Emerald Health Biotechnology España,S.L.U. Chromenic phytocannabinoids, their synthesis and use in treatment or prevention of disease
CA3123773A1 (en) * 2018-12-12 2020-06-18 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl)
CA3128054A1 (en) * 2019-01-31 2020-08-06 Cava Healthcare Inc. Compounds for increasing mhc-i expression and modulating histone deacetylase activity
NL2022614B1 (en) * 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical, phyto-cannabinoid based compositions
EP3937925A1 (en) 2019-03-12 2022-01-19 EPM (IP), Inc. Cannabinoid acid ester compositions and uses thereof
EP3946307A4 (en) * 2019-04-02 2022-12-14 Ulagaraj Selvaraj SOLID NANOPARTICLE FORMULATION OF WATER-INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD MATURATION AND IMMEDIATE DRUG RELEASE AFTER INTRAVENOUS ADMINISTRATION
US12178797B2 (en) 2019-05-03 2024-12-31 Zyus Life Sciences Inc. Formulation for pain management
US12220396B2 (en) 2019-05-03 2025-02-11 Zyus Life Sciences Inc. Formulation for pain management
KR102445087B1 (ko) * 2019-05-03 2022-09-20 자이우스 라이프 사이언시스 아이엔씨. 통증 관리용 제형
AU2020275513A1 (en) * 2019-05-16 2021-12-16 Ramot At Tel-Aviv University Ltd. Cannabinoids and uses thereof
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
CN111184710A (zh) * 2020-03-02 2020-05-22 福建省中科生物股份有限公司 一种环酚的应用和制备方法
WO2021219903A1 (es) * 2020-04-29 2021-11-04 Emerald Health Biotechnology España S.L. Cannabinoides para uso en la supresión de células madre cancerosas
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
CN111773390B (zh) * 2020-07-01 2021-08-20 南京大学 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用
US20220064090A1 (en) * 2020-07-10 2022-03-03 Consiglio Nazionale Delle Ricerche Cannabis extracts and uses thereof
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
CA3182869A1 (en) * 2020-07-22 2022-01-27 John K. Jackson Silver enhanced cannabinoid antibiotics
WO2022043961A1 (en) * 2020-08-31 2022-03-03 Nelson Mandela University Cannabinoid combinations and their use in the treatment of cancer
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US20240041902A1 (en) * 2020-12-08 2024-02-08 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Compositions and methods for the treatment of urothelial cancer
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
US20240108583A1 (en) * 2021-01-25 2024-04-04 LDN Pharma Limited Naltrexone compositions
IL307444A (en) * 2021-04-05 2023-12-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Preparations and methods for the treatment of cancer
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
KR20240116463A (ko) 2021-10-26 2024-07-29 더 유니버시티 오브 뉴캐슬 대마 추출물을 이용한 자궁내막증 및 기타 비암성 부인과 장애의 치료 방법
CA3235077A1 (en) 2021-10-26 2023-05-04 Alex Nance Systems and methods for producing hemp extracts and compositions
KR20240121723A (ko) 2021-10-26 2024-08-09 에코파이버 유에스에이 인코포레이티드 대마 추출물을 사용하여 자궁내막암을 치료하는 방법
US12599617B2 (en) 2021-10-26 2026-04-14 Dove Innovation Pty Limited Methods of treating head and neck cancers with hemp extract
WO2023130161A1 (en) * 2022-01-10 2023-07-13 Dolce Cann Global Pty Ltd Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda) along with an additional active agent
WO2023130160A1 (en) * 2022-01-10 2023-07-13 Dolce Cann Global Pty Ltd Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda).
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2023161921A2 (en) * 2022-02-23 2023-08-31 Cannabotech Ltd. Compositions for use as an adjunctive therapy in the treatment of breast cancer
WO2023239415A1 (en) * 2022-06-08 2023-12-14 Angrow Company Limited Compositions including cannabinoid and use thereof in the manufacture of a medicament for the treatment of inflammation in a subject
WO2023238114A1 (en) * 2022-06-08 2023-12-14 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Combinations and methods for the treatment of cancer
EP4568702A1 (en) 2022-08-12 2025-06-18 Jazz Pharmaceuticals Research UK Limited Oral solid dosage forms comprising cannabinoids
WO2024082014A1 (en) * 2022-10-21 2024-04-25 Dolce Cann Global Pty Ltd Compositions comprising cannabidiolic acid and fatty acids
IL320518A (en) 2022-10-26 2025-06-01 Ecofibre Usa Inc Stabilized compositions containing cannabidiol
IL320517A (en) 2022-10-26 2025-06-01 Ecofibre Usa Inc Methods for treating estrogen-sensitive diseases with cannabis extract
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技（苏州）有限公司 一种高纯度四氢大麻素同系物的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2238707A (en) 1989-12-08 1991-06-12 Peter Bullock Repairing footwear
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
ES2164584A1 (es) 2000-02-11 2002-02-16 Univ Madrid Complutense Terapia con cannabinoides para el tratamiento de tumores cerebrales.
US20040039048A1 (en) 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
ES1045342Y (es) 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
CA2422320A1 (en) 2000-09-14 2002-03-21 The Regents Of The University Of California Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
GB2380129B (en) 2001-02-14 2004-08-11 Gw Pharma Ltd Pharmaceutical formulations
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
EP1482917B1 (en) * 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
US20080057117A1 (en) 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
WO2003091189A1 (en) 2002-04-25 2003-11-06 Virginia Commonwealth University Cannabinoids
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2391865B (en) 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
MX2007012157A (es) 2005-04-01 2008-03-14 Intezyne Technologies Llc Micelas polimericas para suministro de farmacos.
US7968594B2 (en) 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
EP1881757A4 (en) 2005-05-13 2008-09-10 Unimed Pharmaceuticals Inc DRONABINOL TREATMENT OF CHEMOTHERAPY-INDUCED POSSIBLE INCOMPATIBILITY AND ILLUSTRATION
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2439393B (en) 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US20080103193A1 (en) * 2006-10-26 2008-05-01 Trevor Percival Castor Methods for making compositions and compositions for treating pain and cachexia
US20100152238A1 (en) * 2007-03-05 2010-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2449691A (en) * 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
DE602007011766D1 (de) * 2007-10-02 2011-02-17 Vivacell Biotechnology Espana S L Zusammensetzung mit nicht-psychotropen Cannabinoiden zur Behandlung von Entzündungserkrankungen
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2460672B (en) * 2008-06-04 2012-01-04 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma

Also Published As

Publication number Publication date
DK2544682T3 (en) 2016-05-09
JP5785569B2 (ja) 2015-09-30
US9675654B2 (en) 2017-06-13
IL221871A (en) 2017-03-30
GB201004137D0 (en) 2010-04-28
TW201201828A (en) 2012-01-16
JP2013522184A (ja) 2013-06-13
CN102869356A (zh) 2013-01-09
GB2478595B (en) 2018-04-04
SI2544682T1 (sl) 2016-06-30
US8790719B2 (en) 2014-07-29
US20150086653A1 (en) 2015-03-26
TWI461205B (zh) 2014-11-21
SG184016A1 (en) 2012-10-30
GB2478595A (en) 2011-09-14
AU2011225837A1 (en) 2012-11-01
AU2018217273A1 (en) 2018-08-30
KR20130067248A (ko) 2013-06-21
BR112012023017A8 (pt) 2018-04-03
HUE029817T2 (en) 2017-04-28
CA2792722A1 (en) 2011-09-15
EP2544682B1 (en) 2016-02-10
CY1117451T1 (el) 2017-04-26
EP2544682A1 (en) 2013-01-16
PL2544682T3 (pl) 2016-08-31
AU2018217273B2 (en) 2020-03-12
AR080454A1 (es) 2012-04-11
ZA201207574B (en) 2014-09-25
US20180042975A1 (en) 2018-02-15
NZ602953A (en) 2014-09-26
EA201290901A1 (ru) 2013-04-30
CO6630103A2 (es) 2013-03-01
PH12012501782A1 (en) 2012-11-12
MX2012010512A (es) 2012-10-15
WO2011110866A1 (en) 2011-09-15
UA109271C2 (uk) 2015-08-10
HRP20160427T1 (hr) 2016-07-01
US20130059018A1 (en) 2013-03-07
BR112012023017A2 (pt) 2016-05-31
AU2016266059A1 (en) 2016-12-22
ES2569669T3 (es) 2016-05-12

Similar Documents

Publication Publication Date Title
Smith et al. Scolytus and other economically important bark and ambrosia beetles
MX2023003337A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2019008337A (es) Uso de cannabinoides para el tratamiento de epilepsia.
NZ597704A (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
WO2012042404A3 (en) Antimicrobial, antibacterial and spore germination inhibiting activity from an avocado extract enriched in bioactive compounds
PH12021552871A1 (en) Processes for producing lipids
PH12013502148A1 (en) Cannabinoids for use in the treatment of neuropathic pain
WO2011140655A8 (en) Phenolic compositions derived from apple skin and uses thereof
MX364633B (es) Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético.
MY172673A (en) Non-alcohol, beer-taste beverage having substantiality in taste
WO2014047653A3 (en) Methods and compositions for extending shelf life of plant products
SG190738A1 (en) Non-linear acene derivatives and their use as organic semiconductors
WO2012024394A3 (en) Compositions comprising paulownin and/or paulownia extracts and uses thereof
WO2012134169A3 (ko) 조각인 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
WO2012088382A3 (en) Amyris alcohol and its ester for treating acne
WO2012134252A3 (ko) 마자인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
WO2014074765A3 (en) Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
IN2014DN09558A (enExample)
MX342022B (es) Lactonas macrociclicas.
WO2012134167A3 (ko) 비파엽 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
UA104621C2 (ru) Садовая замазка для заживления ран на деревьях
UA112075C2 (uk) Виділений екстракт з рослини ficus arnottiana
UA62955U (ru) Применение экстракта коры осины в качестве средства адаптогенного действия
UA70027U (ru) Ингибитор коррозии
WO2019132826A3 (en) Natural disinfectant solution

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 MAR 2018 BY IP CENTRUM LIMITED

Effective date: 20161022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2019 BY IP CENTRUM LIMITED

Effective date: 20180224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2020 BY IP CENTRUM LIMITED

Effective date: 20190228

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2021 BY DR. STEFFEN SCHWARZ

Effective date: 20200229

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2022 BY BIRGIT KNAACK

Effective date: 20210227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2023 BY PAVIS PAYMENT GMBH

Effective date: 20220303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2024 BY PAVIS PAYMENTS GMBH

Effective date: 20230224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2025 BY BIRGIT KNAACK

Effective date: 20240308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250123